Cancer Family
Malignant Eye Neoplasm
CI-CAN-00000231Explore in graph →
83 active trials2 approved drugs19 evidence items
- NCIt
- C4767
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000231Explore in graph →
Clinical trials
446 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (67)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03746223 | Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | Oct 9, 2019 | clinicaltrials |
| NCT02359851 | Pembrolizumab in Treating Patients With Advanced Uveal Melanoma | terminated | Phase 2 | 5 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT01471054 | Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma | terminated | Phase 2 | 6 | Arman MashayekhiOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01100528 | Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance | completed | Phase 2 | 38 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00121225 | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 2 | Jan 29, 2019 | clinicaltrials |
| NCT00929019 | Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients | terminated | Phase 1 / Phase 2 | 23 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT01293539 | Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma | terminated | Phase 2 | 10 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 27, 2018 | clinicaltrials |
| NCT02654821 | Study With T-cel Receptor Gene Therapy in Metastatic Melanoma(TCR) | unknown | Phase 1 / Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT01200238 | STA-9090(Ganetespib) in Metastatic Ocular Melanoma | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT01814046 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | terminated | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00243061 | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT01961115 | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT00450255 | VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | May 24, 2018 | clinicaltrials |
| NCT01533948 | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 2 | 25 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT01328106 | Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Dec 12, 2017 | clinicaltrials |
| NCT01034787 | Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma | completed | Phase 2 | 11 | AHS Cancer Control AlbertaOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT01252251 | RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01143402 | Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 2 | Jul 26, 2017 | clinicaltrials |
| NCT00072514 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | completed | Phase 2 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT01110135 | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma | completed | Phase 2 | 43 | University of WashingtonOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00482911 | Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma | terminated | Phase 2 | 12 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 27, 2017 | clinicaltrials |
| NCT01857752 | Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala | terminated | Phase 2 | 3 | Stanford UniversityOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT01251978 | Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2) | completed | Phase 2 | 10 | New England Retina AssociatesOTHER | 1 | Oct 19, 2016 | clinicaltrials |
| NCT00906113 | Intra-arterial Chemotherapy for Children With Retinoblastoma | unknown | Phase 1 / Phase 2 | 10 | Hadassah Medical OrganizationOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT00588640 | Study of D-Methadone in Patients With Chronic Pain | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT01393769 | Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage | terminated | Phase 2 | 5 | Hospital Sant Joan de DeuOTHER | 1 | Aug 2, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT00738361 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery | completed | Phase 2 | 4 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00003273 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 3 | Dec 3, 2015 | clinicaltrials |
| NCT00024258 | Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | completed | Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2015 | clinicaltrials |
| NCT00089063 | Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00831844 | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 2 | 116 | National Cancer Institute (NCI)NIH | 3 | Mar 30, 2015 | clinicaltrials |
| NCT00432445 | Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma | terminated | Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 27, 2015 | clinicaltrials |
| NCT00089206 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 7 | University of VirginiaOTHER | 1 | Dec 19, 2014 | clinicaltrials |
| NCT01377025 | A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma(STREAM) | unknown | Phase 2 | 200 | Prof. Dr. med. Max. E. ScheulenOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT00089219 | Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 39 | University of VirginiaOTHER | 1 | Nov 20, 2014 | clinicaltrials |
| NCT00329641 | Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00054639 | Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Oct 9, 2019source: clinicaltrials